{"id":13,"date":"2026-08-17T12:53:22","date_gmt":"2026-08-17T12:53:22","guid":{"rendered":"https:\/\/peptide-doc.com\/learn\/semaglutide\/"},"modified":"2026-09-02T19:41:50","modified_gmt":"2026-09-02T19:41:50","slug":"semaglutide","status":"publish","type":"learn_article","link":"https:\/\/peptide-doc.com\/de\/learn\/semaglutide\/","title":{"rendered":"Semaglutide"},"content":{"rendered":"
\nMETA-TITLE:<\/strong> [TODO: Semaglutide \u2014 GLP-1 Agonist Research Profile | Brand]
\nMETA-DESC:<\/strong> [TODO: Complete semaglutide research profile \u2014 GLP-1 receptor agonist mechanism, STEP trial data, dosing protocols, safety.]\n<\/div>\n

[TODO]<\/span> Hook \u2014 semaglutide as the most widely studied GLP-1 receptor agonist, Novo Nordisk, Ozempic\/Wegovy\/Rybelsus, research landmark<\/p>\n

[IMAGE: Semaglutide molecular structure or research vial]<\/div>\n

What is Semaglutide?<\/h2>\n
    \n
  • [TODO]<\/span> Full name \u2014 Semaglutide, brands: Ozempic (T2D), Wegovy (obesity), Rybelsus (oral)<\/li>\n
  • [TODO]<\/span> Developer \u2014 Novo Nordisk<\/li>\n
  • [TODO]<\/span> Classification \u2014 GLP-1 receptor agonist, 94% homology to human GLP-1<\/li>\n
  • [TODO]<\/span> Forms \u2014 injectable (SC weekly), oral (daily tablet)<\/li>\n
  • [TODO]<\/span> History \u2014 approved 2017 (T2D), 2021 (obesity)<\/li>\n<\/ul>\n

    Mechanism of Action<\/h2>\n
    [IMAGE: GLP-1 receptor signaling pathway diagram \u2014 brain, pancreas, stomach]<\/div>\n
      \n
    • [TODO]<\/span> GLP-1R binding \u2014 hypothalamic appetite centers, POMC\/CART activation, NPY\/AgRP inhibition<\/li>\n
    • [TODO]<\/span> Gastric emptying \u2014 delayed via vagal pathways, increases satiety<\/li>\n
    • [TODO]<\/span> Pancreatic effects \u2014 glucose-dependent insulin secretion, glucagon suppression<\/li>\n
    • [TODO]<\/span> Albumin binding \u2014 C18 fatty acid chain, half-life ~7 days<\/li>\n
    • [TODO]<\/span> DPP-4 resistance \u2014 amino acid modifications prevent degradation<\/li>\n<\/ul>\n

      Research Highlights<\/h2>\n
        \n
      • [TODO]<\/span> STEP 1 \u2014 14.9% body weight reduction (2.4mg, 68 weeks, non-diabetic)<\/li>\n
      • [TODO]<\/span> STEP 2 \u2014 9.6% in T2D population<\/li>\n
      • [TODO]<\/span> STEP 3 \u2014 with intensive behavioral therapy, 16% reduction<\/li>\n
      • [TODO]<\/span> SELECT trial \u2014 20% cardiovascular risk reduction (MACE)<\/li>\n
      • [TODO]<\/span> FLOW trial \u2014 kidney protective effects in CKD + T2D<\/li>\n<\/ul>\n

        Dosing Protocols (Research Context)<\/h2>\n
          \n
        • [TODO]<\/span> Starting \u2014 0.25mg weekly for 4 weeks<\/li>\n
        • [TODO]<\/span> Titration \u2014 0.25mg \u2192 0.5mg \u2192 1mg \u2192 1.7mg \u2192 2.4mg (each 4 weeks)<\/li>\n
        • [TODO]<\/span> Maintenance \u2014 2.4mg weekly (obesity), 1mg weekly (T2D)<\/li>\n
        • [TODO]<\/span> Storage \u2014 2-8\u00b0C, protect from light, 6 weeks in use at room temp<\/li>\n<\/ul>\n

          Safety & Considerations<\/h2>\n
            \n
          • [TODO]<\/span> GI \u2014 nausea (44%), diarrhea (30%), vomiting (24%); typically first 8-12 weeks<\/li>\n
          • [TODO]<\/span> Pancreatitis \u2014 rare, 0.1-0.3%<\/li>\n
          • [TODO]<\/span> Thyroid \u2014 C-cell tumors in rodents, MTC family history contraindication<\/li>\n
          • [TODO]<\/span> Weight regain \u2014 2\/3 regained within 1 year of discontinuation (STEP 4)<\/li>\n
          • [TODO]<\/span> Muscle mass \u2014 concomitant lean mass loss during rapid weight reduction<\/li>\n<\/ul>\n

            Frequently Asked Questions<\/h2>\n
            [FAQ: What is the difference between Ozempic and Wegovy?]<\/div>\n
            [FAQ: How long does it take for semaglutide to reach peak efficacy?]<\/div>\n
            [FAQ: What happens when semaglutide is discontinued?]<\/div>\n
            [FAQ: Can semaglutide be compounded?]<\/div>\n
            [FAQ: What is the recommended reconstitution protocol?]<\/div>\n

            Related Products<\/h2>\n

            [TODO]<\/span> Link to Semaglutide product page + Weight Management category<\/p>\n","protected":false},"excerpt":{"rendered":"

            [META-DESC TODO: Semaglutide research profile \u2014 GLP-1 receptor agonist, STEP trials, mechanism, dosing, safety data.]<\/p>\n","protected":false},"featured_media":0,"template":"","learn_category":[2],"class_list":["post-13","learn_article","type-learn_article","status-publish","hentry","learn_category-weight-management"],"_links":{"self":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/13","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article"}],"about":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/types\/learn_article"}],"version-history":[{"count":1,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/13\/revisions"}],"predecessor-version":[{"id":36,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/13\/revisions\/36"}],"wp:attachment":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/media?parent=13"}],"wp:term":[{"taxonomy":"learn_category","embeddable":true,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_category?post=13"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}